94. Primary sclerosing cholangitis Clinical trials / Disease details

Clinical trials : 142 / Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02239211 (ClinicalTrials.gov)	September 8, 2015	4/9/2014	A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis	A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).	Primary Sclerosing Cholangitis	Drug: BTT1023	University of Birmingham	Biotie Therapies Corp.;University Hospital Birmingham;National Institute for Health Research, United Kingdom	Completed	18 Years	75 Years	All	23	Phase 2	United Kingdom
2	EUCTR2014-002393-37-GB (EUCTR)	06/01/2015	19/11/2014	A clinical trial investigating the use of BTT1023 in patients with PSC	A single arm, two-stage, multi-centre, phase II clinical trial investigating the safety and activity of the use of BTT1023, a human monoclonal antibody targeting vascular adhesion protein (VAP-1), in the treatment of patients with primary sclerosing cholangitis (PSC) - BUTEO: A clinical trial of BTT1023 in patients with PSC	Primary Sclerosing Cholangitis (PSC) MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product Product Code: BTT1023	University of Birmingham	NULL	Not Recruiting			Female: yes Male: yes	59	Phase 2	United Kingdom